DNA ImmunoBody Patent Granted in first market

RNS Number : 0587N

Scancell Holdings Plc

03 September 2013

 



3 September 2013

Scancell Holdings Plc

('Scancell')

DNA ImmunoBody® Patent Granted in first market

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that a patent for its DNA ImmunoBody®  technology has been granted in Australia.  This is the first jurisdiction to approve the DNA patent and is a key landmark on the road to comprehensively protecting Scancell's DNA ImmunoBody® platform technology.

The patent, which covers the DNA ImmunoBody® platform technology and is of importance for the protection of Scancell's entire pipeline of ImmunoBody® vaccines, has also been filed in the US, Europe and other major markets.  The composition of matter patent for SCIB1, Scancell's ImmunoBody® vaccine for the treatment of melanoma, has already been granted in Europe, Turkey and South Africa.

Scancell's protein ImmunoBody® patent has been approved in the US, Europe, Japan and Australia.

Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:

"Our lead ImmunoBody® for melanoma, SCIB1, currently in Phase I/II clinical trials is based on the DNA approach.  The approval of this DNA patent is therefore a very important step in the development and commercialisation of our ImmunoBody® platform.  Scancell continues to build its growing portfolio of intellectual property in parallel with advancing the clinical trial programme on SCIB1."

-ENDS-

For Further Information:

Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc Scancell Holdings Plc	+ 44 (0) 74 2323 0497  + 44 (0) 74 2323 0497
Camilla Hume/Stephen Keys	Cenkos	+ 44 (0) 20 7397 8900
Simon Conway/Mo Noonan	FTI Consulting	+ 44 (0) 20 7831 3113

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

END

 

 

MSCUGUQGBUPWGMP